LinkedIn Icon
March 19-21, 2019 | Boston, MA

 

 

Speakers

Expand/Collapse

Sarah McWhirter
Director – Sting Program
Aduro Biotech

Day One

March 20, 2019

16.00 | Discover how Utilisation of the STING pathway has Bolstered the Effectiveness of PD-L1

Jochem Gokelmeijer
Associate Director
Bristol-Myers Squibb

Mark Paris
Director - Translational Applications
Mitra Biotech

Day One

March 20, 2019

12.00 | A Clinically-Predictive Ex-Vivo Tumor Modelling Platform for Drug Discovery and Development

Mithun Khattar
Scientist & Immuno-oncology lead
Takeda

Workshop A

MARCH 19, 2019

09.00 | Pre-Clinical Development Challenges in Checkpoint Modulators and IO Combinations

Osama Rahma
Assistant Professor
Dana-Faber Cancer Center

Patrick Holder
Scientist
Genentech

Day Two

March 21, 2019

09.40 | Panel Discussion: Mind the Gap - Considering New Targets from Biological Rationale to Therapeutic Protein Delivery

Paul Moore
Vice President - Cell Biology & Immunology
Macrogenics

Day Two

March 21, 2019

14.45 | PD-1-Based Bispecific Antibody Therapies

Raphael Clynes
Vice President - Translational Biology
Xencor

Day Two

March 21, 2019

09.10 | T Cell Engagers, Checkpoints and Cytokines to Broaden Immune Responses to Cancer

Shanthi Ganesh
Associate Director
Dicerna Pharmaceuticals

Willem Overwijk
Vice President Oncology Research
Nektar Therapeutics

Day One

March 20, 2019

11.30 | Supercharging the Tumor Microenvironment: Lessons from NKTR-214 and Opdivo

Viviana Cremasco
Investigator
Novartis

Weiyi Peng
Instructor
University of Houston

Wim Van Schooten
Chief Scientific Officer
Teneobio

Christelle Johnson
Senior Field Applications Scientist
Personalis

Patrick Tricoli
Chief Executive Officer
Nanobiotix

Mark Poznansky
Director, Vaccine and Immunotherapy Center (VIC), Massachusetts General Hospital (MGH) & Associate Professor
Harvard Medical School

Day Two

March 21, 2019

14.15 | Development of Novel Combination Immunotherapies for Ovarian Cancer and Mesothelioma

Sam Fieldwick
Partnerships & Innovations Manager
Beacon Intelligence - Hanson Wade

Day Two

March 21, 2019

08.40 | Immune Checkpoint Combinations and the Cancer Immunity Cycle in Lung Cancer: An Insight by Beacon

John Burke
President, Chief Executive Officer & Co-founder
Applied Biomath

Day One

March 20, 2019

09.40 | Model Aided Drug Invention Case Study: GITR-mediated T cell dynamics in Mouse Tumor Micro Environment

Paul Rennert
President and Chief Scientific Officer
Aleta Biotherapeutics

Day One

March 20, 2019

09.10 | Establishing a New Set of Biological Goals for Checkpoint Inhibitors and IO Combinations

Mark Yore
Manager of Corporate Development
Jounce Therapeutics

Day One

March 20, 2019

08.40 | Navigating the complex ICI-IO landscape – Recent updates and Future Challenges

Amy-Jo Casbon
Immunotherapy & Oncology Scientist
Amgen Inc.

Bei Wang
Staff Scientist
Regeneron

Day One

March 20, 2019

16.30 | T Cell Dysfunction and Combination Immunotherapy

Beth Trehu
Chief Medical Officer
Jounce Therapeutics

Day One

March 20, 2019

12.30 | Lessons Learned from a Clinical Trial Targeting ICOS

Catherine Sabatos-Peyton
Director
Novartis

Day Two

March 21, 2019

13.45 | Overcoming the Suppressive Tumor Microenvironment: Lessons from Preclinical and Translational Checkpoint Studies

09.40 | Panel Discussion: Mind the Gap - Considering New Targets from Biological Rationale to Therapeutic Protein Delivery

Eva Vanamee
Chief Scientific Officer
FusionBio

Day Two

March 21, 2019

09.40 | Panel Discussion: Mind the Gap - Considering New Targets from Biological Rationale to Therapeutic Protein Delivery